Research across Cancer
Related studies from across the Cancer family.
Camrelizumab plus chemotherapy is cost-effective for first-line treatment of advanced squamous non-small-cell lung cancer
Immune Checkpoint Inhibitors Show Cost-Effectiveness for Lung Cancer Treatment
This network meta-analysis evaluates the cost-effectiveness of six immune checkpoint inhibitor-based first-line therapies combined with chem…
New analysis shows specific immune checkpoint inhibitor combinations may be more cost-effective than chemotherapy for advanced lung cancer p…
Trastuzumab Deruxtecan Management of HER2 Positive Metastatic Breast Cancer with Visceral Crisis
Newer drug shows promise for advanced breast cancer and liver issues
A case report highlights the efficacy of trastuzumab deruxtecan in managing visceral crisis in HER2-positive metastatic breast cancer.
A new treatment approach may help patients with advanced breast cancer who are facing a sudden, serious crisis in their liver function.
Evaluating AI and Manual Stromal Immune Cell Quantification in HER2 Positive Breast Cancer
AI tools help predict outcomes for HER2-positive breast cancer
This Phase 3 analysis evaluates how manual, digital, and AI-based sTIL quantification impact prognostic and predictive outcomes in HER2+ bre…
New analysis shows that AI and manual counts of immune cells can help predict how well patients with HER2-positive breast cancer respond to …
Delayed margin formation in lung tumor microwave ablation may occur despite lack of immediate intraprocedural margin
Microwave ablation of lung tumors may show delayed results
This case report describes a single patient with a metastatic lung tumor treated with CT-guided microwave ablation. A well-defined margin ap…
A lung tumor may not show immediate signs of treatment success, but a delayed response can still indicate the procedure worked.
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.